Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)
Mes dernières consult.
Most popular
  Report  
Delayed Quote. Delayed  - 02/23 05:35:05 pm
66.14 EUR   -3.42%
02/21Arix, Fosun in China-focused deal
AQ
02/16UCB : Advances Psoriasis Pipeline with Positive Data at American Aca..
PU
01/31UCB : Transparency Notification
AQ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo UCB
Engages in the research, development, and commercialization of pharmaceutical and biotechnology products

UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.

It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec.

The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

Number of employees : 7 563 persons.
Sales per Businesses
20152016Delta
EUR (in Million)%EUR (in Million)%
Cimzia1,08327.9%1,30731.3% +20.68%
Keppra (Including Keppra XR)737.0019%724.0017.3% -1.76%
Vimpat679.0017.5%814.0019.5% +19.88%
Other Products431.0011.1%---
Neupro258.006.7%302.007.2% +17.05%
Zyrtec (including Zyrtec-D/Cirrus)147.003.8%140.003.4% -4.76%
Xyzal117.003%107.002.6% -8.55%
Venlaflaxine XR90.002.3%90.002.2% 0%
Nootropil52.001.3%46.001.1% -11.54%
Other--310.007.4%-
Briviact--18.000.4%-
Sales per Regions
20152016Delta
EUR (in Million)%EUR (in Million)%
United States1,69443.7%1,85144.3% +9.27%
Other Countries485.0012.5%319.007.6% -34.23%
Germany247.006.4%290.006.9% +17.41%
Japan207.005.3%268.006.4% +29.47%
Other196.005.1%292.007% +48.98%
Emerging Markets192.005%---
Italy154.004%154.003.7% 0%
Spain152.003.9%162.003.9% +6.58%
France150.003.9%161.003.9% +7.33%
Belgium35.000.9%33.000.8% -5.71%
Europe--328.007.9%-
Managers
NameAgeSinceTitle
Jean-Christophe Tellier-2011Chief Executive Officer & Executive Director
Evelyn du Monceau681984Chairman
Charl van Zyl, MBA512017Chief Operating Officer
Detlef Thielgen-2006Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich MD, PhD582006Chief Medical Officer & Executive Vice President
Norman J. Ornstein-2008Independent Director
Albrecht de Graeve632010Independent Director
Charles-Antoine Janssen-2001Director
Jonkheer Cédric van Rijckevorsel, CFA-2014Director
Alice Dautry-Varsat, PhD682015Independent Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 194,505,658 117,260,182 60.3% 6,294,677 3.2% 60.3%
Shareholders
NameEquities%
Financière de Tubize SA 68,076,981 35.0%
Wellington Management Co. LLP 14,004,126 7.20%
UCB SA 6,428,833 3.31%
Capital Research & Management Co. (World Investors) 4,740,024 2.44%
The Vanguard Group, Inc. 3,138,484 1.61%
Schroder Investment Management Ltd. 2,797,702 1.44%
Schwarz Family 2,471,404 1.27%
BlackRock Fund Advisors 2,402,990 1.24%
Norges Bank Investment Management 1,994,994 1.03%
Wellington Management International Ltd. 1,990,643 1.02%
Holdings
NameEquities%Valuation
UCB (UCB) 6,428,8333.31%562,211,989 USD
Dermira Inc (DERM) 1,841,2344.42%52,511,994 USD
Arix Bioscience PLC (ARIX) 3,869,9024.02%10,456,088 USD
Heidelberg Pharma AG (WL6) 1,131,1864.03%4,918,023 USD
Markets and indexes
- Euronext Brussels
- Compartiment A
- BEL 20 / Euronext 100, PEA
Stock Exchange Codes
- Bloomberg Code :  UCB:BB
- Reuters Code :  UCB.BR
- Datastream Code :  B:UCB
Company contact information
UCB
allée de la Recherche 60
BE-1070 Bruxelles, Bruxelles-Capitale
Belgium

Phone : +32 (0)2 559 9999
Fax : +32 (0)2 559 9900
Internet : http://www.ucb.com
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
UCB-0.06%15 758
JOHNSON & JOHNSON-7.02%349 006
NOVARTIS-2.94%222 939
PFIZER-1.33%213 155
ROCHE HOLDING LTD.-9.41%207 036
MERCK AND COMPANY-3.02%148 618
AMGEN4.92%132 428
BRISTOL-MYERS SQUIBB COMPANY7.60%108 890
NOVO NORDISK A/S-4.17%103 898
ABBOTT LABORATORIES3.36%102 678
SANOFI-9.46%100 767
BAYER-5.85%100 069
GLAXOSMITHKLINE-2.00%91 716
ELI LILLY AND COMPANY-8.61%85 390
ASTRAZENECA-7.21%84 103
CELGENE CORPORATION-10.14%70 622
ALLERGAN PLC-2.56%53 014
TAKEDA PHARMACEUTICAL CO LTD-8.37%43 574
SHIRE-22.46%38 453
JIANGSU HENGRUI MEDICINE CO LTD5.06%32 416
ASTELLAS PHARMA INC5.38%29 217
Connections : UCB
FBNet Belgium
The Belgische Commissie Corporate Governance
Koninklijke Luchtvaart Maatschappij NV
Hoechst Marion Roussel, Inc.
Pharmaceutical Research & Manufacturers of America
Ecole Polytechnique
European Federation of Pharmaceutical Industries & Assns
Wallon Institute for Life Lead Sciences
Johann Wolfgang Goethe-Universität Frankfurt am Main
The Campaign Legal Center
Institut Pasteur de Lille
U.S. Capitol Historical Society
Agence National de Recherches sur le Sida et les Hépatites
Flanders-China Chamber of Commerce
Deutsche Akademie der Naturforscher Leopoldina eV
Belgian Luxembourg Chamber of Commerce for Russia & Belarus
Université Libre de Bruxelles
SCR-Sibelco NV
IDS Capital (UK) Ltd.
Biotechnology Innovation Organization
École normale supérieure de Cachan
Bio-Rad Innovations SAS
Institut Pasteur de Montevideo
Institut Curie
Institut Pasteur de Shanghai
Leem Recherche
Shanghai Pasteur Health Research Foundation
Conseil Pasteur-Weizmann
Telenet Group BVBA
Institut Pasteur de Dakar
Alcatel Trade International AG
Institut Pasteur de Hong Kong
Concours Reine Elisabeth
Institute of Science & Technology Austria
The Conference Board, Inc.
Medicen Paris Region
International Business Leaders Advisory Council
Académie des Technologies
© 2018 People , Fundamentals and Ownership    © 2018 Cofisem